NovaBridge Biosciences (NBP) vs Cartesian Therapeutics (RNAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Cartesian Therapeutics (RNAC) has outperformed NovaBridge Biosciences (NBP) over the past year, losing 30.4% versus a loss of 78.2%. Over five years, RNAC leads with a -94.7% price change compared with -98.1% for NBP. Cartesian Therapeutics is the larger company by market cap ($189.7 million vs $146.2 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBP | RNAC |
|---|---|---|
| Share price | $1.26 | $6.27 |
| Market cap | $146.16M | $189.70M |
| 1-day change | -2.33% | -4.71% |
| YTD return | -68.34% | -13.04% |
| 1-year return | -78.16% | -30.41% |
| 5-year return | -98.13% | -94.71% |
| EPS (TTM) | $-0.69 | $-5.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.80M |
| Revenue growth (YoY) | — | -92.81% |
| Net income (latest FY) | $-46.27M | $-130.30M |
| Operating margin | — | -5127.10% |
| Net margin | — | -4658.63% |
| 52-week high | $5.97 | $11.00 |
| 52-week low | $1.26 | $5.60 |
| Distance from 52-week high | -78.89% | -43.00% |
| Analyst consensus | none | none |
| Avg. price target upside | +614.29% | +437.00% |
| Average volume | 390.05K | 131.23K |
| Shares outstanding | 116.00M | 30.26M |
| Employees | 30 | 75 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNAC has outperformed NBP by 47.8 percentage points over the past year.
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Healthcare · Biotechnology · 30 employees
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Healthcare · Biotechnology · 75 employees
NBP vs RNAC FAQ
Which is bigger, NovaBridge Biosciences or Cartesian Therapeutics?
Cartesian Therapeutics (RNAC) is larger, with a market capitalization of $189.70M compared with $146.16M for NovaBridge Biosciences (NBP).
Which stock has performed better over the past year, NBP or RNAC?
RNAC returned -30.41% over the past 12 months, compared with -78.16% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are NovaBridge Biosciences and Cartesian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.